96 Tests PN: A111119

32 Tests PN: A111119T

Components:

45x Ab-conjugated beads (S5P4 - human IFNα2 Ab-bead).

  • 96 Tests PN: A111119A. One vial containing 100 µL of anti-human IFNα2 conjugated to AimPlex Bead S5P4

  • 32 Tests PN: A111119TA. One vial containing 35 µL of anti-human IFNα2 conjugated to AimPlex Bead S5P4

25x Biotin-detection Ab (human IFNα2 Biotin-dAb).

  • 96 Tests PN: A111119B. One vial containing 100 µL of biotinylated anti-human IFNα2.

  • 32 Tests PN: A111119TB. One vial containing 35 µL of biotinylated anti-human IFNα2.

Lyophilized Standard Mix-Human Group 2 Panel A, 10-Plex.

  • 96 & 32 Tests PN: HG2009A. One vial containing lyophilized recombinant human G-CSF, GM-CSF, IFNα2, IL-1α, IL-3, IL-5, IL-7, IL-11, IL-12p40, and IL-13. Note: If multiple analyte kits on the above target list are ordered as a panel, only one vial of standard mix is supplied for those analyte kits. 

Application: Optimal antibody pair and antigen standard for assaying human IFNα2.  Can be multiplexed with other analytes in Human Group 2.  To be used in conjunction with the AimPlex NR Basic Kit (96 Tests PN: P100001, 32 Tests PN: P100001T) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.

Storage:  2-8 C in the dark.

Important: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.

For Research Use Only.  Not for use in diagnostic procedures.

Assay Specifications:

  • Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate

  • Sensitivity (LOD): < 5 pg/mL

  • Quantitation range:

  • LLOQ: < 10 pg/mL

  • ULOQ: > 5,000 pg/mL

  • Standard dose recovery: 70-130%

  • Intra-assay CV: < 10%

  • Inter-assay CV: < 20%

  • Cross-reactivity of analytes in Human Group 2: Negligible

  • Sample volume: 15 µL/test

Description:

Interferon alpha 2 (Accession P48551) is a member of the Type I Interferon cytokine family. IFN-alpha 2 is a key cytokine within the innate immune response system. IFN-alpha 2 is only secreted by cells that have been infected with a virus. It was the first cytokine to be commercialized by the pharmaceutical industry, therefore, has been studied extensively by researchers. There is a correlation between patients with melanoma, who have been treated with IFNα2 and an increased presence of auto-antibodies. As a treatment, IFNα2 would be degraded by digestive enzymes and must be administered by injection. Recombinant IFNα2 may be used to treat hepatitis B and C and some cancers such as renal cell carcinoma and melanoma.

References:

  1. Antonelli G, Scagnolari C, Moschella F, Proietti E. Twenty-five years of type I interferon-based treatment: a critical analysis of its therapeutic use. Cytokine Growth Factor Rev. 2015; 26(2): 121-31. Doi: 10.1016/j.cytogfr.2014.12.006.

  2. Gogas H, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med. 2006; 354(7): 709-18. Doi: 10.1056/NEJMoa053007.

  3. Paul F, Pellegrini S, Uze G. IFNA2: The prototypic human alpha interferon. Gene. 2015; 567(2): 132-137. Doi: 10.106/j.gene.2015.04.087.